Jason Engel, MD
Urology · Washington, DCNPI 1285797605
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,200 of the $11,637 with a category attached, or 61.9%. Boston Scientific accounts for 84.5% of it on its own, with 27 other manufacturers making up the rest.
Across 133 payments — averaging $87.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Endo Pharmaceuticals Inc.$186
- Intuitive Surgical$176
- Johnson & Johnson$169
- Pfizer$157
- Astellas Pharma US Inc$149
- plus $970 from 22 others
Across 115 payments — averaging $6344.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$566K
- Davol Inc.$138K
- Ferring International Pharmascience Center US$14K
- Spectrum Pharmaceuticals Inc.$8K
- Ferring Pharmaceuticals AS$3K
What the payments were for
- Speaking & faculty fees$7,20062%
- Travel & lodging$1,0559%
- Food & beverage$3,17127%
- Education$360%
- Gifts$1762%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 60 | $9,830 |
| Endo Pharmaceuticals Inc. | 9 | $186 |
| Intuitive Surgical | 1 | $176 |
| Johnson & Johnson(3 entities) | 8 | $169 |
| Pfizer | 6 | $157 |
| Astellas Pharma US Inc | 8 | $149 |
| Axonics, Inc. | 8 | $137 |
| Dornier Medtech America, Inc | 1 | $135 |
| Urogen Pharma, Inc. | 4 | $105 |
| Telix Pharmaceuticals | 3 | $91 |
| Dendreon Pharmaceuticals LLC | 3 | $82 |
| Myovant Sciences Inc. | 4 | $74 |
| AbbVie | 3 | $51 |
| Olympus America Inc. | 1 | $33 |
| Urovant Sciences Inc | 1 | $24 |
| Therapeuticsmd, Inc. | 1 | $23 |
| Davol Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Bayer | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
| Coloplast | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 700 CXR RTE KIT$4,200
- AMS 700$4,125
- GENERAL ERECTILE DYSFUNCTION$211
- Da Vinci Surgical System$176
- Dornier MedTech$135
How this compares
$11,637 in reported general payments places this provider in the 80th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 35 | $522,001 |
| OrgovyxRelugolix | 60 | $168,541 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 145 | $4,604 |
| Tamsulosin Hcl | 145 | $2,223 |
| Solifenacin Succinate | 31 | $2,162 |
| CefuroximeCefuroxime Axetil | 97 | $962 |
| Finasteride | 82 | $892 |
| Dutasteride | 18 | $708 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $353 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 42 | $232 |
| Bicalutamide | 11 | $202 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $191 |
| Levofloxacin | 45 | $128 |
| Metronidazole | 13 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $149 | $522,00135 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $22 | $168,54160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Keith KowalczykWashington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.